Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia (WM): Results from iNNOVATE.

Alessandra Tedeschi; Meletios A. Dimopoulos; Judith Trotman; Ramón Garcia-Sanz; David MacDonald; Beatrice Mahe; Charles Herbaux; Leonard T. Heffner; Constantine Si Lun Tam; Marzia Varettoni; Maria Lia Palomba; Jeffrey Matous; Chaim Shustik; Efstathios Kastritis; Steven P. Treon; Jianling Li; Erik Poulsen; Bernhard Hauns; Christian Buske; Veronique Leblond

doi:10.1200/JCO.2019.37.15_SUPPL.8018

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia (WM): Results from iNNOVATE.

Alessandra Tedeschi
, Meletios A. Dimopoulos
, Judith Trotman
, Ramón Garcia-Sanz
, David MacDonald
, Beatrice Mahe
, Charles Herbaux
, Leonard T. Heffner
, Constantine Si Lun Tam
, Marzia Varettoni
, Maria Lia Palomba
, Jeffrey Matous
, Chaim Shustik
, Efstathios Kastritis
, Steven P. Treon
, Jianling Li
, Erik Poulsen
, Bernhard Hauns
, Christian Buske
, Veronique Leblond

Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy;
National and Kapodistrian University of Athens
Concord Repatriation General Hospital
Hospital Universitario de Salamanca, Salamanca, Spain;
University of Ottawa
Hematology, University Hospital, Nantes, France;
Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion, Lille, France;
Emory University
Peter MacCallum Cancer Centre
Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;
Memorial Sloan-Kettering Cancer Center
Colorado Blood Cancer Institute, Denver, CO;
McGill University Health Centre
Harvard University
Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA;
University of Ulm
Hôpital Pitié-Salpêtrière, Paris, France;

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	37
Issue number	15
DOIs	https://doi.org/10.1200/JCO.2019.37.15_SUPPL.8018
State	Published - May 26 2019
Externally published	Yes

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1200/JCO.2019.37.15_SUPPL.8018License: Unspecified

Cite this

Tedeschi, A., Dimopoulos, M. A., Trotman, J., Garcia-Sanz, R., MacDonald, D., Mahe, B., Herbaux, C., Heffner, L. T., Tam, C. S. L., Varettoni, M., Palomba, M. L., Matous, J., Shustik, C., Kastritis, E., Treon, S. P., Li, J., Poulsen, E., Hauns, B., Buske, C., & Leblond, V. (2019). Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia (WM): Results from iNNOVATE. Journal of Clinical Oncology, 37(15). https://doi.org/10.1200/JCO.2019.37.15_SUPPL.8018

Tedeschi, A, Dimopoulos, MA, Trotman, J, Garcia-Sanz, R, MacDonald, D, Mahe, B, Herbaux, C, Heffner, LT, Tam, CSL, Varettoni, M, Palomba, ML, Matous, J, Shustik, C, Kastritis, E, Treon, SP, Li, J, Poulsen, E, Hauns, B, Buske, C & Leblond, V 2019, 'Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia (WM): Results from iNNOVATE.', Journal of Clinical Oncology, vol. 37, no. 15. https://doi.org/10.1200/JCO.2019.37.15_SUPPL.8018

@article{f50c69f42cbb424fa03fdb14b4a461e6,

title = "Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia (WM): Results from iNNOVATE.",

author = "Alessandra Tedeschi and Dimopoulos, \{Meletios A.\} and Judith Trotman and Ram{\'o}n Garcia-Sanz and David MacDonald and Beatrice Mahe and Charles Herbaux and Heffner, \{Leonard T.\} and Tam, \{Constantine Si Lun\} and Marzia Varettoni and Palomba, \{Maria Lia\} and Jeffrey Matous and Chaim Shustik and Efstathios Kastritis and Treon, \{Steven P.\} and Jianling Li and Erik Poulsen and Bernhard Hauns and Christian Buske and Veronique Leblond",

note = "8018 Background: Anemia and fatigue can impair quality of life in patients (pts) with WM. Ibrutinib (ibr) as single agent or in combination with RTX is FDA-approved for WM. In pts with RTX-refractory WM, single-agent ibr induced meaningful improvements in PROs (Trotman, EHA 2017).",

year = "2019",

month = may,

day = "26",

doi = "10.1200/JCO.2019.37.15\_SUPPL.8018",

language = "American English",

volume = "37",

journal = "Journal of Clinical Oncology",

number = "15",

}

TY - JOUR

T1 - Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia (WM): Results from iNNOVATE.

AU - Tedeschi, Alessandra

AU - Dimopoulos, Meletios A.

AU - Trotman, Judith

AU - Garcia-Sanz, Ramón

AU - MacDonald, David

AU - Mahe, Beatrice

AU - Herbaux, Charles

AU - Heffner, Leonard T.

AU - Tam, Constantine Si Lun

AU - Varettoni, Marzia

AU - Palomba, Maria Lia

AU - Matous, Jeffrey

AU - Shustik, Chaim

AU - Kastritis, Efstathios

AU - Treon, Steven P.

AU - Li, Jianling

AU - Poulsen, Erik

AU - Hauns, Bernhard

AU - Buske, Christian

AU - Leblond, Veronique

N1 - 8018 Background: Anemia and fatigue can impair quality of life in patients (pts) with WM. Ibrutinib (ibr) as single agent or in combination with RTX is FDA-approved for WM. In pts with RTX-refractory WM, single-agent ibr induced meaningful improvements in PROs (Trotman, EHA 2017).

PY - 2019/5/26

Y1 - 2019/5/26

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8018

U2 - 10.1200/JCO.2019.37.15_SUPPL.8018

DO - 10.1200/JCO.2019.37.15_SUPPL.8018

M3 - Article

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15

ER -

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenstrom macroglobulinemia (WM): Results from iNNOVATE.

Disciplines

Access to Document

Other files and links

Cite this